Last reviewed · How we verify
NCT03948802
Evaluation of IL-33 in Patients With the Acute Ischemic Stroke
trial testing Interleukine 33 test in blood plasma in Ischemic Stroke in 50 participants. Completed in 6 March 2024.
31 December 2023
Quick facts
| Lead sponsor | Jan Biziel University Hospital No 2 in Bydgoszcz |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 January 2019 |
| Primary completion | 31 December 2023 |
| Estimated completion | 6 March 2024 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- Interleukine 33 test in blood plasma
Conditions studied
- Ischemic Stroke — all drugs for Ischemic Stroke →
Sponsor
Jan Biziel University Hospital No 2 in Bydgoszcz
Who can join
Adults 18 to 99, any sex, with Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Aim of the study is to evaluate the usefulness of interleukin 33 in the blood plasma in patients with the acute ischemic stroke of the brain in relation to mode of treatment (thrombolysis, thrombectomy, no treatment), risk factors in correlation with other inflammatory state markers (hsCRP, morphology with smear ). Blood is collected on the first and seventh days of stroke. The purpose is to clarify utility of IL 33 as a biomarker of acute stroke.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Therapeutic Opportunities of Interleukin-33 in the Central Nervous System.
Sun Y, Wen Y, Wang L, Wen L, et al · · 2021 · cited 35× · PMID 34079543 · DOI 10.3389/fimmu.2021.654626
Verify or expand the search:
- PubMed search for NCT03948802
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ischemic Stroke
Currently open trials in the same condition.
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
- NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
- NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
- NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting
Other Jan Biziel University Hospital No 2 in Bydgoszcz trials
Trials by the same sponsor.
- NCT07190092 — Deep Anterior Cerebellar Stimulation in Treatment of Poststroke Spasticity and Motor Function Impairment. · NA · recruiting
- NCT03957395 — Comparison of Effectiveness of Tonic, High Frequency and Burst Spinal Cord Stimulation in Chronic Pain Syndromes · NA · unknown
- NCT03948399 — The Prevalence of a Low Ankle-Brachial Index in Acute Cerebral Ischemia. · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03948802 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jan Biziel University Hospital No 2 in Bydgoszcz
- Last refreshed: 15 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03948802.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing